TY - JOUR AU - MacNeil, Jessica AU - Medah, Isaïe AU - Koussoubé, Daouda AU - Novak, Ryan AU - Cohn, Amanda AU - Diomandé, Fabien V.K. AU - Yelbeogo, Denis AU - Kambou, Jean Ludovic AU - Tarbangdo, Tiga AU - Ouédraogo-Traoré, Rasmata AU - Sangaré, Lassana AU - Hatcher, Cynthia AU - Vuong, Jeni AU - Mayer, Leonard AU - Djingarey, Mamoudou AU - Clark, Thomas AU - Messonnier, Nancy T1 - Neisseria meningitidis Serogroup W, Burkina Faso, 2012 T2 - Emerging Infectious Disease journal PY - 2014 VL - 20 IS - 3 SP - 402 SN - 1080-6059 AB - In 2010, Burkina Faso became the first country to introduce meningococcal serogroup A conjugate vaccine (PsA-TT). During 2012, Burkina Faso reported increases in Neisseria meningitidis serogroup W, raising questions about whether these cases were a natural increase in disease or resulted from serogroup replacement after PsA-TT introduction. We analyzed national surveillance data to describe the epidemiology of serogroup W and genotyped 61 serogroup W isolates. In 2012, a total of 5,807 meningitis cases were reported through enhanced surveillance, of which 2,353 (41%) were laboratory confirmed. The predominant organism identified was N. meningitidis serogroup W (62%), and all serogroup W isolates characterized belonged to clonal complex 11. Although additional years of data are needed before we can understand the epidemiology of serogroup W after PsA–TT introduction, these data suggest that serogroup W will remain a major cause of sporadic disease and has epidemic potential, underscoring the need to maintain high-quality case-based meningitis surveillance after PsA–TT introduction. Download MP3  Length: 1:40 KW - meningococcal meningitis KW - serogroup W135 KW - menincoccal meningitis KW - Burkina Faso KW - serogroup A meningococcal conjugate vaccine KW - bacteria KW - serogroup W meningococcal meningitis KW - children DO - 10.3201/eid2003.131407 UR - https://wwwnc.cdc.gov/eid/article/20/3/13-1407_article ER - End of Reference